Stocks To Watch For Oct 13: Avenue Supermarts, Tata Motors, Tata Capital listing, BLS Int and more

From Avenue Supermarts to Tata Motors, these are some of the important stocks to watch out for going into Monday’s trading session on October 13.

From Avenue Supermarts to Tata Motors, these are some of the important stocks to watch out for going into Monday’s trading session on October 13.

From renewed hostilities between US and China, to earnings reactions, listing of the largest IPO of the year and an important day for Tata Motors as well, Monday promises to be an action-packed session for India’s equity markets.

SEBI Chairperson Tuhin Kanta Pandey emphasised that investor trust remains the foundation of country’s financial ecosystem, adding that the market regulator’s long-term goal was to build “resilient institutions, not just successful businesses.”

UTI is the second fund manager to curb new investments into silver-based funds this week. On Thursday, Kotak Mahindra Asset Management Company also temporarily suspended new investments into a Silver ETF Fund of Fund.

The order for debarment has been issued on the account of allegations, including court cases and multiple complaints from passport applicants. The company added that it will assess the order and rely on legal remedies to address the issue.

This comes just a day after the company, in another expansion in the redevelopment space, this time in Mumbai, said it has been selected as the preferred partner for the redevelopment of four residential societies. The project spans around 1.65…

JPMorgan had maintained its “neutral” rating Avenue Supermarts with a price target of ₹4,350 in a note last week, stating that the revenue growth during the quarter will weigh on the near-term stock price.

With Fed rate cuts ahead and US growth slowing, HSBC Asset Management’s Global CIO Xavier Baraton favours selective exposure to emerging markets, led by India.

This marks a month-on-month decline, as, in August, the company’s total Premium in the life insurance department stood at ₹1,484.8 crore. In addition, the gross direct premium underwritten stood at ₹2,063 crore.

Lupin also added that the Mumbai-based pharma company is ‘committed to being compliant with CGMP standards across all our facilities.